tradingkey.logo
Search
Markets
Watchlist
News
Analysis
Tools
Stock Screener
English
繁体中文
ไทย
Tiếng việt
简体中文
Español
Português
Deutsch
한국어
日本語
tradingkey.logo
Search

Ultragenyx Pharmaceutical Inc

RARE
Add to Watchlist
24.910USD
-1.130-4.34%
Close 07-31 16:00（ET）Quotes delayed by 15 min
2.45BMarket Cap
LossP/E TTM

Ultragenyx Pharmaceutical Inc

24.910
-1.130-4.34%
Overview
Financials
Discussions
Analysis
Company
Financial SummaryIncome StatementBalance SheetCash Flow Statement

Overview

Financials

Discussions

Analysis

Company

Financial SummaryIncome StatementBalance SheetCash Flow Statement

RARE Financials

See Ultragenyx Pharmaceutical Inc's financials through an all-in-one data dashboard designed for smart investors. This provides you with financial analysis by organizing complex financial statements into customizable views. Access the latest annual financial report or break down performance quarter-by-quarter using the income statement, balance sheet, and cash flow statement. With real-time financial indicators at your fingertips, monitoring a company's market health over time has never been easier.

Ultragenyx Pharmaceutical Inc Earnings Date

Latest Release
Aug 4, 2026
EPS / Forecast
--/-1.23
Revenue / Forecast
--/180.24M
See Upcoming Earnings >>
Period
FY2025 Earnings
Revenue(YoY)
673.00M
20.13%
EPS(YoY)
-5.83
7.24%
Analyst Rating
BUY
2026/08/02
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
FY2021Q2
Financial Indicators
EPS
-17.20%-1.84
7.60%-1.29
-29.33%-1.81
23.19%-1.17
22.52%-1.57
8.13%-1.39
37.24%-1.40
32.58%-1.52
13.10%-2.03
29.91%-1.52
---2.23
---2.25
---2.33
---2.16
---7.96
----
----
----
----
----
Revenue
-2.36%136.00M
25.72%207.28M
14.65%159.93M
13.24%166.50M
27.99%139.29M
29.42%164.88M
42.27%139.49M
35.75%147.03M
8.30%108.83M
23.27%127.39M
8.10%98.05M
21.23%108.31M
25.72%100.50M
23.93%103.35M
11.09%90.70M
2.72%89.34M
-19.58%79.94M
-8.91%83.39M
0.22%81.65M
40.94%86.97M
Net Profit
-22.45%-185.00M
3.62%-128.56M
-35.12%-180.41M
12.65%-114.95M
11.49%-151.08M
-8.28%-133.38M
16.37%-133.52M
17.66%-131.60M
-4.09%-170.68M
18.86%-123.19M
34.87%-159.65M
-1.05%-159.83M
-7.65%-163.97M
-23.99%-151.83M
-235.77%-245.11M
-29.19%-158.16M
-11.88%-152.32M
-410.01%-122.46M
-6.03%-73.00M
-583.62%-122.43M
Net Margin
-25.42%-136.03%
23.34%-62.02%
-17.86%-112.81%
22.86%-69.04%
30.84%-108.46%
16.34%-80.90%
41.21%-95.71%
39.34%-89.51%
3.88%-156.83%
34.18%-96.70%
---162.82%
---147.57%
---163.16%
---146.91%
---213.70%
----
----
----
----
----
Gross Margin
-1.87%77.94%
-4.36%85.84%
-2.86%82.50%
0.77%86.18%
-5.32%79.42%
-0.87%89.75%
-4.35%84.93%
-5.86%85.53%
-4.46%83.89%
-4.55%90.54%
--88.79%
--90.85%
--87.80%
--94.85%
--91.15%
----
----
----
----
----
Debt to assets ratio
--88.35%
--75.33%
--69.66%
--64.81%
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Income Statement
Revenue
-2.36%136.00M
25.72%207.28M
14.65%159.93M
13.24%166.50M
27.99%139.29M
29.42%164.88M
42.27%139.49M
35.75%147.03M
8.30%108.83M
23.27%127.39M
8.10%98.05M
21.23%108.31M
25.72%100.50M
23.93%103.35M
11.09%90.70M
2.72%89.34M
-19.58%79.94M
-8.91%83.39M
0.22%81.65M
40.94%86.97M
Operating profit
-18.23%-169.00M
7.36%-113.28M
-29.47%-170.89M
7.28%-107.89M
13.55%-142.94M
-0.19%-122.28M
9.04%-131.99M
21.35%-116.36M
-7.30%-165.35M
16.19%-122.05M
35.53%-145.10M
-4.49%-147.96M
-12.79%-154.10M
-41.99%-145.63M
-150.55%-225.07M
-71.06%-141.59M
-28.21%-136.63M
-6.75%-102.56M
-78.53%-89.83M
-31.28%-82.78M
Net Profit
-22.45%-185.00M
3.62%-128.56M
-35.12%-180.41M
12.65%-114.95M
11.49%-151.08M
-8.28%-133.38M
16.37%-133.52M
17.66%-131.60M
-4.09%-170.68M
18.86%-123.19M
34.87%-159.65M
-1.05%-159.83M
-7.65%-163.97M
-23.99%-151.83M
-235.77%-245.11M
-29.19%-158.16M
-11.88%-152.32M
-410.01%-122.46M
-6.03%-73.00M
-583.62%-122.43M
Balance Sheet
Current assets
-6.03%657.00M
16.38%951.00M
-19.56%643.21M
-25.38%719.79M
17.31%699.15M
11.60%817.12M
33.45%799.61M
37.39%964.64M
-22.23%595.97M
-17.16%732.18M
-40.83%599.19M
3.48%702.14M
8.31%766.34M
3.19%883.90M
19.58%1.01B
-28.54%678.54M
-33.93%707.52M
-33.87%856.60M
-2.88%846.88M
4.80%949.49M
Total current liabilities
11.43%325.00M
11.58%384.00M
19.30%340.02M
7.47%293.24M
18.77%291.67M
22.72%344.15M
12.22%285.01M
11.66%272.87M
12.56%245.57M
7.36%280.44M
11.71%253.98M
10.76%244.38M
30.47%218.18M
44.02%261.21M
67.26%227.36M
73.64%220.64M
31.63%167.23M
-4.35%181.37M
-32.43%135.93M
-42.17%127.07M
Total assets
-1.21%1.30B
1.90%1.53B
-22.62%1.19B
-19.29%1.31B
0.37%1.31B
0.83%1.50B
24.25%1.54B
23.42%1.62B
-5.52%1.31B
-3.52%1.49B
-23.50%1.24B
-0.71%1.31B
-0.05%1.38B
1.51%1.55B
9.00%1.62B
-12.68%1.32B
-13.38%1.38B
-13.48%1.52B
17.06%1.48B
15.10%1.51B
Total liabilities
31.39%1.52B
29.31%1.60B
-0.87%1.17B
-3.21%1.15B
-0.53%1.16B
2.10%1.24B
-1.81%1.18B
0.32%1.19B
0.33%1.17B
1.90%1.22B
4.94%1.21B
84.00%1.18B
97.91%1.16B
98.88%1.19B
108.60%1.15B
18.93%642.55M
8.18%587.61M
-0.88%599.84M
-8.48%551.13M
-12.64%540.27M
Total equity
-251.41%-229.00M
-127.83%-73.00M
-95.43%16.16M
-63.40%158.29M
7.83%151.25M
-4.76%262.30M
1015.68%353.83M
235.13%432.42M
-36.38%140.26M
-21.87%275.41M
-93.24%31.71M
-80.97%129.03M
-72.32%220.48M
-61.79%352.49M
-49.79%468.83M
-30.25%678.07M
-24.48%796.42M
-20.08%922.56M
40.15%933.67M
39.76%972.17M
Cash Flow Statement
Net operating income
-18.34%-197.00M
-25.57%-99.83M
-36.46%-91.42M
-40.68%-108.27M
12.72%-166.47M
5.25%-79.50M
43.16%-67.00M
33.74%-76.96M
-21.59%-190.73M
7.13%-83.90M
-23.63%-117.87M
-50.36%-116.16M
-33.48%-156.87M
-66.24%-90.34M
-59.84%-95.34M
-18.21%-77.26M
26.25%-117.52M
12.98%-54.34M
3.74%-59.65M
-174.82%-65.36M
Net investment
-140.87%-49.00M
-170.32%-72.25M
142.53%117.18M
17.52%71.17M
26.96%119.89M
196.00%102.73M
-528.50%-275.50M
-39.08%60.56M
-15.16%94.44M
37.64%-107.02M
139.72%64.30M
25.58%99.42M
397.91%111.30M
-348.49%-171.60M
-297.11%-161.86M
291.94%79.17M
79.52%-37.36M
-29.46%69.06M
57.44%-40.76M
52.12%-41.25M
Net financing
----
12272.63%394.19M
-99.98%2.00K
-78.27%83.65M
370.69%157.00K
-99.04%3.19M
-55.72%11.17M
1065.78%384.94M
91.97%-58.00K
17466.95%330.61M
-94.87%25.23M
465.70%33.02M
-144.79%-722.00K
-97.80%1.88M
6414.93%491.88M
-53.78%5.84M
-87.26%1.61M
-82.49%85.72M
-60.54%7.55M
-64.74%12.63M

FAQs

What is the total revenue of Ultragenyx Pharmaceutical Inc?

According to Ultragenyx Pharmaceutical Inc's FY2025 earnings report, its total revenue reached 673.00M, with a year-on-year change of 560.23M.

What are the current assets of Ultragenyx Pharmaceutical Inc?

According to Ultragenyx Pharmaceutical Inc's FY2025 earnings report, its current assets were 951.00M, with a year-on-year change of 16.38.

What are the total assets of Ultragenyx Pharmaceutical Inc?

According to Ultragenyx Pharmaceutical Inc's FY2025 earnings report, its total assets of Ultragenyx Pharmaceutical Inc were 1.53B, with a year-on-year change of 1.90.

What are the total liabilities of Ultragenyx Pharmaceutical Inc?

According to Ultragenyx Pharmaceutical Inc's FY2025 earnings report, its total liabilities of Ultragenyx Pharmaceutical Inc were 1.60B, with a year-on-year change of 29.31.

What is the total equity of Ultragenyx Pharmaceutical Inc?

According to Ultragenyx Pharmaceutical Inc's FY2025 earnings report, its total equity of Ultragenyx Pharmaceutical Inc was -73.00M, with a year-on-year change of -127.83.

What is the net operating income of Ultragenyx Pharmaceutical Inc?

According to Ultragenyx Pharmaceutical Inc's FY2025 earnings report, its net operating income of Ultragenyx Pharmaceutical Inc was -535.00M, with a year-on-year change of 0.18.

What is the net investment of Ultragenyx Pharmaceutical Inc?

According to Ultragenyx Pharmaceutical Inc's FY2025 earnings report, its net investment of Ultragenyx Pharmaceutical Inc was 236.00M, with a year-on-year change of 1428.23.

What is the net financing of Ultragenyx Pharmaceutical Inc?

According to Ultragenyx Pharmaceutical Inc's FY2025 earnings report, its net financing of Ultragenyx Pharmaceutical Inc was 478.00M, with a year-on-year change of 19.73.

What is the Earnings Per Share (EPS) of Ultragenyx Pharmaceutical Inc?

According to Ultragenyx Pharmaceutical Inc's FY2025 earnings report, its Earnings Per Share (EPS) was -5.83, with a year-on-year change of 7.24.

What is the net income of Ultragenyx Pharmaceutical Inc?

According to Ultragenyx Pharmaceutical Inc's FY2025 earnings report, its net income was -575.00M, with a year-on-year change of -1.02.

What is the net margin of Ultragenyx Pharmaceutical Inc?

According to Ultragenyx Pharmaceutical Inc's FY2025 earnings report, its net profit margin was -85.44, with a year-on-year change of 15.91.

What is the gross margin of Ultragenyx Pharmaceutical Inc?

According to Ultragenyx Pharmaceutical Inc's FY2025 earnings report, its gross margin was 83.80, with a year-on-year change of -2.90.

What is the debt-to-asset ratio of Ultragenyx Pharmaceutical Inc?

According to Ultragenyx Pharmaceutical Inc's FY2025 earnings report, its debt-to-asset ratio was 75.33, with a year-on-year change of 30.22.

What is the Return on Equity (ROE) of Ultragenyx Pharmaceutical Inc?

According to Ultragenyx Pharmaceutical Inc's FY2025 earnings report, its Return on Equity (ROE) was -656.03, with a year-on-year change of -205.84.

What is the Return on Assets (ROA) of Ultragenyx Pharmaceutical Inc?

According to Ultragenyx Pharmaceutical Inc's FY2025 earnings report, its Return on Assets (ROA) was -37.89, with a year-on-year change of 0.34.

What is the operating profit of Ultragenyx Pharmaceutical Inc?

According to Ultragenyx Pharmaceutical Inc's FY2025 earnings report, its operating profit was -535.00M, with a year-on-year change of 0.18.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.
General Terms of Use
Privacy Policy
Cookie Policy